The gamma delta T wave is cresting as industry leaders such as Adicet Bio, Leucid, Century, Imcheck, IN8bio, Sanofi and Takeda race to demonstrate the clinical benefit and efficacy of gamma delta T therapies, spanning cell-based to antibody and small molecule approaches.

Estimates suggest that by 2030, the global gamma delta T cell cancer therapy market is projected to reach US$400 million. Driven by the increasing prevalence of cancer worldwide and the rising awareness and demand for novel and personalized medicine, gamma delta T cell therapy represents one of the most T cell therapies in clinical development.

Spurred by early evidence of clinical efficacy, the industry returns in 2023 armed with more subset-specific and clinical mechanistic understanding, snowballing investment, and growing expert end-to-end teams.

As immuno-oncology steps into the spotlight, there has never been a better time for the gamma delta T therapies industry to come together to contrast subsets, characterize mechanisms of action, and optimize product design to develop globally accessible, solid tumor therapies.